DANBURY, Conn., July 16, 2009 (GLOBE NEWSWIRE) -- Penwest Pharmaceuticals Co. (Nasdaq:PPCO) today announced the results of its Phase Ib clinical trial of A0001, a compound the Company is developing for the treatment of mitochondrial diseases. Drs. Amale Hawi, Senior Vice President, Pharmaceutical Development, and Thomas Sciascia, Senior Vice President & Chief Medical Officer, will be presenting these results at the Friedreich’s Ataxia Therapeutics Meeting on Friday, July 17, 2009, in Philadelphia, PA.
